Skip to content

#BIS

0 items today
Oct 22Thu
  1. pv magazine (Global)

    T1 Energy announces Commerce waiver to import up to 1.725 GW of solar cells ahead of Section 232 tariffs

    T1 Energy, a Texas-based module maker, announced it received a Department of Commerce waiver allowing it to import up to 1.725 GW of solar cells for its module assembly operations in Wilmer, Texas, without penalty for stockpiling under the Section 232 tariffs that take effect December 4, 2026, when polysilicon and silicon-based solar products become subject to a 15% tariff alongside minimum import prices. Ahead of that date, Commerce's Bureau of Industry and Security issued an emergency rule setting criteria for evidence of stockpiling, import prohibition penalties for noncompliance and a process for companies to obtain a waiver.

  2. pv magazine USA

    T1 Energy says Commerce granted Section 232 stockpiling waiver for 1.725 GW of solar cell imports

    T1 Energy announced that the Department of Commerce granted it a waiver allowing it to import up to 1.725 GW of solar cells for its module assembly operations in Wilmer, Texas, without penalty for stockpiling under the Section 232 tariffs that take effect December 4, 2026, when polysilicon and silicon-based solar products become subject to a 15% tariff and minimum import prices. Ahead of that date, Commerce's Bureau of Industry and Security issued an emergency rule setting criteria for evidence of stockpiling, import prohibition penalties for noncompliance and a process for companies to obtain a waiver.

Sep 22Tue
  1. Federal Register · BIS (EAR / Entity List)

    BIS defines zero-tariff specialty pharmaceuticals and eligible jurisdictions under Proclamation 11020

    BIS issued a notice defining the pharmaceutical products and listing the jurisdictions eligible for a zero ad valorem Section 232 tariff rate under Proclamation 11020 of April 2, 2026, covering orphan-indication drugs and associated ingredients, nuclear medicines, plasma derived therapies, fertility drugs, cell therapy products, gene therapy products, antibody drug conjugates, chemical, biological, radiological and nuclear medical countermeasures, and animal health. Products and associated ingredients receive the zero rate if they are of a jurisdiction with a current or forthcoming trade and security framework agreement or meet an urgent U.S. health need.